Ingenus v. Hetero USA: Cyclophosphamide Patent Claim Defeated on Summary Judgment
Ingenus Pharmaceuticals brought a patent infringement action in the Delaware District Court against Hetero USA and Hetero Labs over US10993952B2, a patent covering cyclophosphamide injection solutions. Judge Jennifer L. Hall granted defendants’ motion for summary judgment after just 405 days, delivering a full merits win for the Hetero entities without trial.
Hetero defeats Ingenus cyclophosphamide suit at summary judgment in Delaware
Ingenus Pharmaceuticals, LLC filed suit on 11 September 2024 in the United States District Court for the District of Delaware (Case No. 1:24-cv-01025) against Hetero USA, Inc., Hetero Labs, Ltd., and Hetero Labs Limited, asserting infringement of US10993952B2. The patent covers cyclophosphamide injection solutions at a concentration of 200 mg/ml — a formulation used in oncology and immunosuppressive therapy — in dosage strengths of 1 g/5 ml, 2 g/10 ml, and 500 mg/2.5 ml.
The case closed on 21 October 2025 when Judge Jennifer L. Hall granted defendants’ motion for summary judgment on all of Ingenus’s claims. The court entered judgment on the merits in favour of the Hetero defendants, meaning the dispute was resolved through dispositive motion practice rather than a full trial. A merits-based summary judgment win is legally significant: it represents a court finding that no genuine dispute of material fact existed that could support Ingenus’s infringement claims, foreclosing any straightforward re-filing of the same assertions.
At 405 days from filing to closure, the case resolved considerably faster than the typical Hatch-Waxman lifecycle, which often extends two to three years through claim construction and trial. The public record does not disclose the precise ground on which summary judgment was granted — whether non-infringement, invalidity, or both — leaving the precise doctrinal basis uncertain. The outcome nonetheless strengthens Hetero’s ability to market its cyclophosphamide products and raises questions for Ingenus about the commercial durability of its formulation patent portfolio in this dosage segment.
Filing to Judgment on the merits for Defendant in 405 days
405-day case duration — resolved pre-trial via summary judgment, faster than median Hatch-Waxman district court litigation
Summary judgment for Hetero: what the merits ruling means for both parties
Summary judgment on the merits: a full defence win without trial
Summary judgment is granted when a court finds no genuine dispute of material fact and the moving party is entitled to judgment as a matter of law. A merits-based ruling here means the court assessed the substance of Ingenus’s infringement claims — not merely procedural defects — and found them legally insufficient. This is a more powerful outcome for Hetero than a dismissal without prejudice, as the judgment is entered on the merits.
Fed. R. Civ. P. 56 — merits rulingIngenus’s infringement claims extinguished; re-litigation risk limited
A judgment on the merits against the plaintiff operates as a final adjudication on the claims brought. Ingenus cannot simply refile the same infringement assertions against the same defendants on the same patent without confronting res judicata principles. The ruling leaves the patent nominally in force but practically weakened as an enforcement tool against the Hetero entities for these cyclophosphamide product configurations.
Claim extinguished on meritsHetero cleared to market cyclophosphamide solutions; patent barrier removed
The judgment in favour of Hetero USA, Hetero Labs Ltd., and Hetero Labs Limited confirms these entities can proceed with their cyclophosphamide injection products — 500 mg/2.5 ml, 1 g/5 ml, and 2 g/10 ml at 200 mg/ml — free from this particular patent assertion by Ingenus. The summary judgment win also signals a robust prior art or claim scope argument that may be relevant in related proceedings or against other asserters of similar formulation patents.
Freedom to commercialiseOncology generic market: formulation patents face tougher enforcement landscape
This outcome is consistent with a broader trend in which district courts grant summary judgment in Hatch-Waxman cases where the asserted patent’s claims are narrow formulation parameters that generic ANDA filers can design around or challenge on the merits. Competitors in the cyclophosphamide injectable space may view this ruling as a signal that US10993952B2 poses diminished blocking risk, potentially accelerating generic market entry at these concentration levels.
Generic entry risk reducedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Ingenus Pharmaceuticals, LLC | Company | Specialty pharmaceutical company — holder of US10993952B2 covering cyclophosphamide injection formulationsSearch in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Generic pharmaceutical manufacturer and its Indian parent entities marketing cyclophosphamide injection productsSearch in Eureka ↗ |
| Co-Defendant | Hetero Labs, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Chidambaram S. Iyer | Attorney | Counsel for Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel Taylor | Attorney | Counsel for Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | John T. Callahan | Attorney | Counsel for Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lawrence Roman Rachuba | Attorney | Counsel for Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael R. Dzwonczyk | Attorney | Counsel for Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Neal C. Belgam | Attorney | Counsel for Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Smith, Katzenstein & Jenkins LLP | Law Firm | Representing Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Corey Weinstein | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Neal Seth | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Wesley E. Weeks | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order is unambiguous: judgment is entered on the merits in favour of all three Hetero defendants following a granted motion for summary judgment on Ingenus’s infringement claims. The use of ‘judgment on the merits’ language is legally operative — it is a final adjudication that forecloses Ingenus from reasserting the same claims against these parties. The order does not specify the ground (non-infringement, invalidity, or unenforceability), which is consistent with summary judgment practice but leaves the precise doctrinal basis undisclosed in the public record. For Hetero, the ruling removes the immediate legal cloud over its cyclophosphamide injectable products in the US market.
US10993952B2 — Cyclophosphamide injection solution formulation
US10993952B2 (application number US15/551507) protects cyclophosphamide injection solution formulations at a concentration of 200 mg/ml, covering commercially relevant dosage strengths including 500 mg/2.5 ml, 1 g/5 ml, and 2 g/10 ml. Cyclophosphamide is a nitrogen mustard alkylating agent with established use in oncology (lymphomas, leukaemias, solid tumours) and immunosuppression. The patent represents a formulation-level protection strategy — rather than protecting the active molecule itself, it claims specific solution parameters, concentration, and potentially stabilisation characteristics of the ready-to-use injectable presentation.
Formulation patents on established oncology injectables are commercially significant because they can extend effective market exclusivity beyond the original compound patent expiry. US10993952B2 sits in a competitive space where multiple generic manufacturers have sought FDA approval for cyclophosphamide injectable products. The patent’s defeat at summary judgment in this case suggests its claim scope may be more limited than Ingenus’s enforcement posture implied. Competitors and ANDA filers in the injectable cyclophosphamide segment should assess whether Ingenus holds continuation or divisional patents covering related formulation parameters that could generate follow-on litigation.
Should you run an FTO against US10993952B2 for cyclophosphamide injectables?
Any company developing, manufacturing, or seeking ANDA approval for cyclophosphamide injection solutions at or near 200 mg/ml concentration — particularly in 500 mg, 1 g, or 2 g unit-dose formats — should treat US10993952B2 as a primary FTO target. Although Hetero prevailed on summary judgment, the patent remains granted and nominally in force. Ingenus may pursue other generic filers on the same claims, and the undisclosed basis of the summary judgment leaves open whether the specific product parameters of a third party’s formulation would face the same outcome.
PatSnap Eureka’s FTO Search Agent allows R&D and regulatory teams to map product specifications directly against the claim language of US10993952B2 and identify any related continuation, divisional, or family patents held by Ingenus. Eureka can also surface prosecution history and prior art cited during examination — critical context for assessing whether a non-infringement or invalidity argument similar to Hetero’s could be constructed for a different product formulation. Proactive FTO analysis before ANDA filing reduces downstream litigation exposure materially.
Run a freedom-to-operate analysis on US10993952B2 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical formulation patent cases in Delaware District Court
Explore related Hatch-Waxman infringement actions involving injectable oncology and specialty drug formulation patents litigated in the Delaware District Court.
What this case signals for the oncology injectable IP landscape
A pre-trial merits defeat in Delaware raises critical questions for pharmaceutical formulation patent strategy and generic market entry planning.
Summary judgment defeats signal formulation patent vulnerability in injectables
When a district court resolves an infringement action on summary judgment rather than proceeding to trial, it typically signals that the asserted claims lacked sufficient factual support on a key element — often claim construction, non-infringement, or prior art. Innovators holding formulation patents on established oncology drugs should audit claim scope against ANDA-filer product specifications proactively.
Hetero’s multi-entity structure adds jurisdictional complexity for future plaintiffs
With Hetero USA, Hetero Labs Ltd., and Hetero Labs Limited all named as defendants, this case illustrates the complexity of pursuing Indian generic manufacturers operating through US distribution subsidiaries. Future plaintiffs must ensure their infringement theories reach each entity’s specific role in manufacture, importation, and sale to avoid dispositive motion risk.
Ingenus v Hetero — key questions answered
Judge Jennifer L. Hall of the Delaware District Court granted Hetero’s motion for summary judgment on 21 October 2025, entering judgment on the merits in favour of all three Hetero defendants. Ingenus’s infringement claims under US10993952B2 were fully extinguished. The case closed after 405 days without proceeding to trial.
US10993952B2 (application US15/551507) covers cyclophosphamide injection solution formulations at 200 mg/ml concentration. The products at issue were unit-dose injectables in three strengths: 500 mg/2.5 ml, 1 g/5 ml, and 2 g/10 ml. Cyclophosphamide is an alkylating agent widely used in oncology and immunosuppressive therapy. The patent protects specific formulation parameters of a ready-to-use injectable rather than the active compound itself.
A summary judgment on the merits means the court found no genuine dispute of material fact sufficient to support Ingenus’s infringement claims, entitling Hetero to judgment as a matter of law. Unlike a procedural dismissal, a merits ruling precludes Ingenus from bringing the same claims against the same defendants again under res judicata principles. It is a complete legal victory for Hetero without requiring a full trial.
Not necessarily. The court’s order does not specify whether summary judgment was based on non-infringement, invalidity, or both. If the ruling rested on non-infringement grounds specific to Hetero’s product, the patent may remain a viable enforcement tool against third parties with differently specified formulations. The patent itself remains granted and in force. Other ANDA filers should conduct independent FTO analysis rather than relying on this outcome alone.
Ingenus named three Hetero entities: Hetero USA, Inc. (the US distribution subsidiary), Hetero Labs, Ltd., and Hetero Labs Limited (Indian manufacturing parents). Naming multiple related entities is a common plaintiff strategy in Hatch-Waxman litigation to capture the full chain of infringement — manufacturing, importation, and sale — and to prevent a defendant from evading judgment by isolating liability in one entity. All three defendants prevailed on summary judgment.
PatSnap Eureka searches patents and litigation data to answer instantly.